National- and state-level impact and cost-effectiveness of nonavalent HPV vaccination in the United States

Authors:

Abstract
Significance: Vaccination protects against human papilloma virus (HPV)-induced cervical cancer, but coverage varies markedly across the United States. The nonavalent vaccine produces greater health benefits than the bivalent and quadrivalent vaccines at a lower societal cost. Because of the impact of herd immunity, any expansion in coverage will be much more effective in reducing cancer incidence and healthcare costs if targeted in those states with the lowest coverage. Because of interstate migration and the long duration between HPV infection and resultant cervical cancer, much of the benefit of vaccination will be realized beyond a state’s borders. Therefore, both cervical cancer incidence and expenditure can be substantially reduced if the states coordinate policies to promote expansion of coverage, particularly for the new nonavalent vaccine.
Funding Information
  • HHS | National Institutes of Health (2 U01 GM087719)
  • HHS | National Institutes of Health (5 U01 GM105627)
  • Gouvernement du Canada | Canadian Institutes of Health Research (450024)
  • James S. McDonnell Foundation (220020114)

This publication has 64 references indexed in Scilit: